David Rodman sells shares; Mineralys Therapeutics (MLYS) Form 144 lists multiple dispositions
Rhea-AI Filing Summary
Mineralys Therapeutics (MLYS) reported insider dispositions. David Rodman reported multiple sales of Common Stock over January–March 2026, including a broker-assisted cashless exercise reported on 03/12/2026 covering 6,348 shares. The filing lists several prior dispositions in the three months before that date with individual sale dates and share counts.
Positive
- None.
Negative
- None.
Insights
Routine insider dispositions reported; timing and amounts are disclosed.
The filing lists a broker-assisted cashless exercise of 6,348 shares on 03/12/2026 and multiple prior sales in January–March 2026. These entries document transactions by a reporting person rather than corporate action.
Cash-flow treatment and any use of proceeds are not detailed in the excerpt; subsequent SEC filings would show further position context or plan disclosures.